Objectives: 1) Survey on the use of drug treatment of dyslipidemia in Vietnam Heart Institute; 2) Assessing the reasonableness ofthe use of drug treatment of dyslipidemia in studied patients. Objects - Methods: retrospective study 293 patients received combination treatment with anti-dyslipidemia based on the criteria of the clinical characteristics, cardiovascular riskcharacteristics, the characteristics of dyslipidemia, treatment of dyslipidemia, analyze drug use, dosage and drug interactions. Results: 293 patients, of which 176 male patients (60.1 percent) and 117 female patients (39.9 percent), mean age 63.9 + or - 9.1; 274 patients athigh cardiovascular riskand veryhigh (93.5 percent) were included in the study. Pathological characteristics: 140 patients with acute coronary syndrome (47.8 percent), 47 patients with acute myocardial infarction (16.0 percent), 87 patients with hypertension (29.7 percent), 19 patients with is chemicheart disease (6.5 percent) of which coordinating with medicaland other clinical conditions such as diabetes, heart failure, stroke, lower limbarterial disease due toatherosclerosis artery. Nearly 50 percent of patients with low HDL levels less than 1mmol/l. 216 patients inpatientsat high risk and very high LDL -C 1.8mmol/l. Treatment of dyslipidemia is mainlystatin (rosuvastatinis 50.3 percent, 43.8 percent of atorvastatin) with conventional doses. The common drug interactions should be noted that atorvastatin-omeprazole (45.5 percent) but did not showed clinical events. Conclusion: The drug is used to specifya reasonable, safe, in accordance with the regulations, swell as recommendations in the world.
- Đăng nhập để gửi ý kiến